OBJECTIVES The aim of this study was to investigate the association between high on-treatment platelet reactivity BACKGROUND Platelet function testing may be used to optimize antiplatelet therapy in high-risk patients,
H igh on-treatment platelet reactivity (HPR) has emerged as a risk factor for stent thrombosis and major adverse cardiovascular events (MACE) in patients who receive clopidogrel after percutaneous coronary intervention (PCI) (1) . Multiple factors can contribute to these pharmacodynamic findings (2) . In particular, genetic factors have been shown to be associated with poor responsiveness to clopidogrel (3) , but their impact on the risk of MACE is controversial (4, 5) . Moreover, the low positive predictive value of HPR and the absence of large-scale randomized clinical trials supporting the use of platelet function testing question the utility of routine assessment of platelet reactivity in patients undergoing PCI (6) . Accordingly, current guidelines do not endorse routine use of platelet function testing, but they suggest that in selected patients at high risk of a poor outcome after PCI, platelet function testing can be implemented to optimize antiplatelet therapy (7) . However, identification of these patients remains challenging.
Prospectively developed for the SYNTAX (Synergy Between Percutaneous Coronary
Intervention With Taxus and Cardiac Surgery) trial (8) , the SYNTAX score (SS) has been shown to be associated with an increased risk of mortality, myocardial infarction (MI), and stent thrombosis in patients with non-ST-segment elevation acute coronary syndromes (NSTEACS) undergoing PCI (9) . The relationship between the SS and the presence of HPR for the risk of MACE, however, has never been investigated. Other unsolved dilemmas include the relative prognostic value of platelet function testing versus pharmacogenetic information, the incremental prognostic value of the determination of platelet reactivity over time, and the existence of a therapeutic window for platelet reactivity. On this background, in the present study, we sought to investigate the following: 1) the association between platelet reactivity and the SS for the risk of MACE in patients with NSTEACS undergoing PCI treated with clopidogrel; 2) the association between genetic variants involved in clopidogrel-mediated platelet effects and the risk of MACE; 3) the incremental prognostic value of the platelet reactivity measured at several time points; and 4) the existence of a therapeutic window of platelet reactivity, which could be associated with a low risk of both ischemic and bleeding events. 
METHODS
Exclusion criteria were allergy or intolerance to aspirin and clopidogrel, need for concomitant oral anticoagulant therapy, cardiogenic shock, any contraindication or inability to comply with dualantiplatelet therapy for 1 year, treatment with prasugrel or ticagrelor, and major comorbidities associated with life expectancy <1 year. The study was approved by the local ethics committee at each participating center, and all patients provided written informed consent.
PLATELET FUNCTION TESTING. Platelet reactivity was measured using the VASP assay (Biocytex, Marseille, France) using flow cytometric technique as previously described (10) , and it was expressed as platelet reactivity index (PRI). HPR was defined as a PRI >50% as previously reported to be associated with ischemic recurrences and in agreement with expert consensus (11) . The VASP assay was used to measure platelet reactivity because results are not affected by the use of glycoprotein IIb/IIIa inhibitors, which are commonly used in patients with NSTEACS, particularly among enrolling centers in this study.
The PRI was determined at 3 time points: before PCI, at hospital discharge, and at 1 month after PCI. Clinical events were then correlated with the closest PRI determination performed before the event, so that periprocedural events were correlated with the PRI measured before PCI, events between discharge and 1 month with the PRI measured at hospital discharge, and events between 1 month and 1 year with the PRI determined at 1 month. Table 1 .
PCI was performed according to the standard of care. Platelet reactivity index (PRI) was determined before percutaneous coronary intervention (PCI), at hospital discharge, and 1 month after PCI.
Platelet Reactivity and MACE was performed using iPLEX Gold technology, as pre- by Kaplan-Meier analysis, and differences were compared using the log-rank test. ROC curves were generated to determine the discriminative power of the PRI and the SS for the risk of ischemic and bleeding events. The optimal cutoff point was calculated by determining the value with the greatest sum of sensitivity and specificity. Stepwise multivariable Cox regression analyses were performed to assess independent predictors of MACE between 1 month and 1 year. Several multivariable models were constructed to determine the additive prognostic value of the PRI and the SS after adjusting for main confounders known to have an impact on the risk of MACE, as suggested by previous studies (16, 17) . The prognostic accuracy of each model was assessed by the C-statistic, the integrated discrimination improvement (IDI), and the net reclassification improvement (18, 19) . The following variables were included in the stepwise multivariable models: clin- Values are median (interquartile range) or % (n/N). *Clopidogrel treatment for at least 7 days before the procedure.
ACEI ¼ angiotensin-converting enzyme inhibitor; CABG ¼ coronary artery bypass graft; NSTEMI ¼ non-ST-segment elevation myocardial infarction; PCI ¼ percutaneous coronary intervention.
Palmerini et al. Table 1 and Online Table 2 The proportion of patients with PRI>50% was 69% before PCI, 49% at hospital discharge, and 41% 1 month after PCI.
Abbreviations as in Table 1 . Values are % (n/N) or median (interquartile range).
NA ¼ not available; PRI ¼ platelet reactivity index; SNP ¼ single nucleotide polymorphism.
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Platelet Reactivity and MACE in Figure 2 , the percentage of patients with HPR was 69% before PCI, 49% at hospital discharge, and 41% at 1 month. The association between genetic variants modulating clopidogrel effects and 1-month PRI values is shown in Figure 3A) , or with an SS $15 ( Figure 3B ) had significantly higher rates of MACE compared with patients without HPR or an SS <15, respectively. Moreover, as shown in Table 3 , patients without HPR had significantly higher rates of bleeding than patients with HPR. There was no significant difference between the discriminatory Table 4 .
As shown in Figure 3C , in the period between Table 3 ).
MULTIVARIABLE ANALYSES. Multivariable analyses with or without HPR and the SS are shown in Table 5 (models 1 through 4 Clinical outcomes between PCI and hospital discharge (stratified by pre-procedural PRI)* MACE ‡ 3.1 (22) Tables 1 and 2 .
in those with an SS <15 (OR: 2.91, 95% CI: 0.70 to 11.92, p ¼ 0.14). However, no significant interaction was apparent between the 2 variables (p ¼ 0.87).
Performance measures in models with or without HPR and the SS are shown in Online Table 4 THERAPEUTIC WINDOW. The optimal cutoff values determined by ROC analyses for the risk of MACE (PRI >51%) or BARC bleeding $2 (PRI #40%) in the period between 1 month and 1 year were used to stratify patients into 3 groups: group 1 had a PRI #40%, group 2 had a PRI between 40% and 51%, and group 3 had a PRI >51%. As shown in Figure 4 , the incidence of net adverse clinical events was 5.8% in group 1, 3.2% in group 2, and 6.2% in group 3 (p ¼ 0.37). Survival free from major adverse cardiac events (MACE) in patients stratified by the platelet reactivity index (PRI) (A), the SYNTAX score (SS) (B), and both PRI and SS (C).
DISCUSSION
Patients were stratified by tertiles of SS, and then the upper tertile of SS ($15) was compared with pooled mid and lower SS tertiles. Outcomes between hospital discharge and 1 year (stratified by PRI at hospital discharge) † Tables 2 and 3 .
Palmerini et al. other abbreviations as in Table 3 . 
